Clinical Trials

Beyond First Line Therapy

A Study to Evaluate KIN-3248 (study drug) in Patients with Advanced Tumors Who Have FGFR2 and//or FGFR3 Gene Alterations

LEARN MORE

Targeted Therapy

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

LEARN MORE

Chemotherapy

ZW25-201: A Phase 2 Study of Zanidatamab (ZW25; bispecific antibody) Plus First-line Chemotherapy in HER2-Expressing Cancers, Including Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, and Colorectal Cancer

LEARN MORE

Beyond First Line Therapy

Safety and Tolerability of TNG908 in Patients with MTAP-deleted Solid Tumors

LEARN MORE

Targeted Therapy

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

LEARN MORE

Beyond First Line Therapy

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

LEARN MORE

Beyond First Line Therapy

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

LEARN MORE

Beyond First Line Therapy

ICP-CL-00303

LEARN MORE

Beyond First Line Therapy

Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC)

LEARN MORE

Immunotherapy

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

LEARN MORE

Beyond First Line Therapy

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

LEARN MORE

Other Novel Therapies

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

LEARN MORE